Skip to main content
SpringerLink
Log in

Use of biochemical markers to study and follow patients with osteoarthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Osteoarthritis is characterized by progressive destruction of articular cartilage and subchondral bone and synovial reaction. Radiologic findings that form the basis of the diagnosis of osteoarthritis are poorly sensitive to detect early disease and for monitoring progression of joint damage. Blood-based proteomic analyses suggest that biochemical alterations can be observed well before radiologic damage is evidenced. New cartilage-specific markers, including assays for type II collagen synthesis and degradation, have been developed. Recent prospective studies indicate that blood and urine levels of these new markers are associated with progression of joint damage. Biological markers respond rapidly to treatment and therefore will certainly play an important role in the development and the monitoring of disease-modifying therapies. Because osteoarthritis involves different tissues and complex biologic processes, a combination of different biochemical markers appears to be the most promising diagnostic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gray ML, Eckstein F, Peterfy C, et al.: Toward imaging biomarkers for osteoarthritis. Clin Orthop Relat Res 2004, 427:(Suppl):S175-S181.

    Article  PubMed  Google Scholar 

  2. Marshall KW, Zhang H, Yager TD, et al.: Blood-based biomarkers for detecting mild osteoarthritis. Osteoarthritis Cartilage 2005, 13:861–871.

    Article  PubMed  CAS  Google Scholar 

  3. Liao H, Wu J, Kuhn E, et al.: Use of mass spectrometry identify protein biomarkers of disease severity in the synovial.uid and serum of patients with rheumatoid arthritis. Arthritis Rhem 2005, 50:3792–3803.

    Article  Google Scholar 

  4. Xiang Y, Sekine T, Nakamura H, et al.: Proteomic surveillance of autoimmunity in osteoarthritis: identification triosephosphate isomerase as an autoantigen in patients with osteoarthritis. Arthritis Rheum 2004, 50:1511–1521. An intriguing study that underscores the potential importance of autoimmunity in osteoarthritis and the application of proteomics discovery of new biochemical markers.

    Article  PubMed  CAS  Google Scholar 

  5. Lamers RJAN, van Nessselrooij JHJ, Kraus VB, et al.: Identi cation of a urinary profile associated with osteoarthritis. Osteoarthritis Cartilage 2005, 13:162–168. The first evidence of a unique urinary metabolite profifle in patients with ostoearthritis.

    Article  Google Scholar 

  6. Ling QM, Patel D, Zhan M, et al.: Changes in selected proteins associated with osteoarthritis development in the Baltimore Longitudinal study of aging (BSLA). Arthritis Rheum 2005, 52(Suppl):S256.

    Google Scholar 

  7. Garnero P, Sharif M, Charni N, et al.: A 5 year longitudinal study of type II collagen synthesis and degradation and their association with disease progression in early knee osteoarthritis. Arthritis Rheum 2005, 52(Suppl):S74.

    Article  Google Scholar 

  8. Rousseau JC, Sandell LJ, Delmas PD, Garnero P: Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. Human Reproduction. Methods Mol Med 2004, 101:25–38. This study described in detail the technical development of an immunoassay for a promising marker of cartilage synthesis.

    PubMed  CAS  Google Scholar 

  9. Garnero P, Desmarais S, Charni N, Percival MD: The type II collagen fragments HELIX-II and CTX-II reveal distinct enzymatic pathways of cartilage collagen degradation: Diagnostic and therapeutic implications in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2005, 44(Suppl):S56.

    Google Scholar 

  10. Charni N, Juillet F, Garnero P: Urinary type II collagen helical peptide (Helix II) as a new biochemical marker cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005, 52:1081–1090. A report of a new type II collagen degradation fragment which provides evidence that combination of markers reflecting different mechanisms of cartilage degradation is more effective than a marker alone to identify patients with RA at high risk for progression.

    Article  PubMed  CAS  Google Scholar 

  11. Garnero P, Conrozier T, Juillet F, et al.: Urinary type II collagen helical peptide (HELIX-II) levels are increased patients with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2005, 64(Suppl 3):OP0117.

    Google Scholar 

  12. Deberg M, Labasse A, Christgau S, et al.: New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthrtitis and rheumatoid arthritis. Osteoarthritis Cartilage 2005, 13:258–265. An example of using post-translational modifications (nytrosilation of tyrosine residues) of proteins for developing process-speci biochemical markers of osteoarthritis.

    Article  PubMed  Google Scholar 

  13. Deberg M, Labasse AH, Collette J, et al.: One year increase Coll 2-1, a new marker of type II collagen is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005, 13:258–265.

    Article  PubMed  Google Scholar 

  14. Verzijl N, Banlk RA, Tekoppele JM, DeGroot J: Ageing and osteoarthritis: a different perspective. Curr Opin Rheumatol 2003, 15:616–622. An excellent review of the role of non-enzymatic glycation in the physiopathology of ostoearthritis.

    Article  PubMed  Google Scholar 

  15. Senolt L, Braun M, Olejarova M, et al.: Increased pentosidine, an advanced glycation end product, in serum and synovial.uid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Ann Rheum Dis 2005, 64:886–890.

    Article  PubMed  CAS  Google Scholar 

  16. Glasson SS, Askew R, Sheppard B, et al.: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644–648.

    Article  PubMed  CAS  Google Scholar 

  17. Skoumal M, Haberhauer G, Kolarz G, et al.: Serum cathepsin K levels of patients with lonstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 2005, 7:565–570.

    Article  Google Scholar 

  18. Garnero P, Sornay-Rendu E, Arlot M, et al.: Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 2004, 50:3137–3144. One of the.rst studies investigating the total body contribution to systemic levels of a biochemical marker of cartilage degradation by radiographic assessment of multiple joints.

    Article  PubMed  Google Scholar 

  19. Meulenbelt I, Kloppenburg M, Kroon HM, et al.: Urinar y CTX-II levels are associated with radiographic subtypes of osteoarthritis (OA) in hip, knee, and facet joints in subject with familial OA at multiple sites: the GARP study. Ann Rheum Dis 2005, Aug 3 [Epub ahead of print].

  20. Moscowitz RW, Holderbaum D, Hooper MM: Total quantitative osteoarthritis load (TQOL) assessment tool: a proposed methodology for biomarker correlations. Arthritis Rheum 2005, 52(Suppl):S71.

    Google Scholar 

  21. Crisione LG, Elliot AL, Stabler T, et al.: Variation of serum hyaluronan with activity in individual with knee osteoarthritis. Osteoarthritis Cartilage 2005, 13:837–840.

    Article  Google Scholar 

  22. Kerstin UG, Studbendorff JJ, Schmidt MC, Bruggemann G-P: Changes in knee cartilage volume and serum COMP concentration after running exercise. Osteoarthritis Cartilage 2005, 13:925–934.

    Article  Google Scholar 

  23. Mundermann A, Dyrby CO, Andriacchi TP, King KB: Serum concentration of oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. Osteoarthrtis Cartilage 2005, 13:34–38.

    Article  Google Scholar 

  24. Elliot AL, Kraus VB, Luta G, et al.: Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 2005, 52:105–111. A large population based-study showing the influence of age, sex, and ethnicity on serum HA but still demonstrating the strong independent association of this synovitis marker with radiologic osteoarthritis of knee and hip

    Article  Google Scholar 

  25. Gineyts E, Mo JA, Ko A, et al.: Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004, 63:857–861.

    Article  PubMed  CAS  Google Scholar 

  26. Ding C, Garnero P, Cicuttini F, et al.: Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Osteoarthritis Cartilage 2005, 13:198–205.

    Article  PubMed  Google Scholar 

  27. Garnero P, Peterfy C, Zaim S, Schoenharting M: Bone marrow abnormality on magnetic resonance imaging is associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005, 52:2822–2829. The.rst study relating bone marrow edema by MRI with a biochemical marker of type II collagen degradation in knee osteoarthritis.

    Article  PubMed  CAS  Google Scholar 

  28. Reijman M, Hazes JM, Bierna-Zeinstra SM, et al.: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004, 50:2471–2476. The largest and longer study of urinary CTX-II as a prognostic marker for progression of knee and hip osteoarthritis.

    Article  PubMed  CAS  Google Scholar 

  29. Sharif M, Kirwan JR, Elson CJ, et al.: Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over.ve years. Arthritis Rheum 2004, 50:2479–2488. This longitudinal 5 year study shows that radiologic disease progression is non linear in knee osteoarthritis and that serum COMP can track this phasic pattern.

    Article  PubMed  CAS  Google Scholar 

  30. Lohmander LS, Brandt KD, Mazzuca SA, et al.: Use of plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 2005, 52:3160–3167. One of the few longitudinal study using state of the art radiography to validate biochemical markers as a predictor of disease progression

    Article  PubMed  CAS  Google Scholar 

  31. Garnero P, Mazières B, Guéguen A, et al.: Crossectional association of ten molecular markers of bone, cartilage and synovium with disease activity and radiological joint damage in hip osteoarthritis patients: the ECHODIAH Cohort. J Rheumatol 2005, 32:697–703.

    PubMed  CAS  Google Scholar 

  32. Mazieres B, Garnero P, Gueguen A, et al.: Molecular markers of cartilage breakdown and synovitis are strong independent predictors of structural progression of hip osteoarthritis. The ECHODIAH cohort. Ann Rheum Dis, In press. The largest longitudinal study in hip osteoarthritis investigating 10 different biochemical markers and showing that the combination of a cartilage degradation marker with a synovitis marker predicts independently and additively disease progression.

  33. Cibere J, Thorne A, Kopec JA, et al.: Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial employing biomarkers. J Rheumatol 2005, 32:896–902.

    PubMed  CAS  Google Scholar 

  34. Ravn P, Warning L, Christgau S, Christiansen C: The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. Bone 2004, 35:1216–1221.

    Article  PubMed  CAS  Google Scholar 

  35. Christgau S, Tanko LB, Cloos PAC, et al.: Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogenreceptor modular (SERM). Menopause 2004, 11:508–518. This study describes a new potential animal model of cartilage degeneration and shows the chondroprotective effects of SERMs in this particular model.

    Article  PubMed  Google Scholar 

  36. Spector TD, Conaghan PG, Buckland-Wright JC, et al.: Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the brisk: randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7:R625-R633. The.rst clinical study of the bisphosphonate risedronate in knee osteoarthritis showing dose dependent response of a biochemical marker of cartilage degradation.

    Article  PubMed  CAS  Google Scholar 

  37. Garnero P, Bingham C, Aronstein W, et al.: Treatment with risedronate reduced urinary CTX-II, a specific biochemical marker of cartilage type II collagen degradation in a 24-month study of knee OA. Arthritis Rheum 2004, 50(Suppl):S656.

    Article  Google Scholar 

  38. Landewé R, Geusens P, Maarten B, et al.: Markers for type II collagen breakdown predict the effect of disease modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis: the Cobra study. Arthritis Rheum 50:1390–1399. In this study the magnitude of the changes of urinary CTX-II after 3 months was predictive of radiologic progression at 5 years in patients with early RA treated with a combined therapy. These data suggest that biological markers may be valid surrogate markers for treatment efficacy in clinical trials of DMARDs.

Download references

Author information

Authors and Affiliations

  1. Synarc, Molecular Markers, Le Buroparc Batîment T4, 16 rue Montbrillant, 69003, Lyon, France

    Patrick Garnero PhD, DSc

Authors
  1. Patrick Garnero PhD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Garnero PhD, DSc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garnero, P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 8, 37–44 (2006). https://doi.org/10.1007/s11926-006-0023-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0023-5

Keywords

Search

Navigation